Stockreport

Salarius regains full Nasdaq compliance ahead of planned merger with Decoy Therapeutics [Seeking Alpha]

Salarius Pharmaceuticals, Inc.  (SLRX) 
PDF The compliance milestone supports Salarius' planned merger with Decoy Therapeutics, announced in January 2025. SLRX shares down 5.5% premarket on Monday. More on Sa [Read more]